Pulsed Field Ablation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Components (Catheters and Generators), By Indication (Atrial Fibrillation and Non-Atrial Fibrillation), By End Use (Inpatient and Outpatient), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.13 Billion
CAGR (2026-2031)	9.71%
Fastest Growing Segment	Catheters
Largest Market	North America
Market Size (2031)	USD 1.97 Billion

Market Overview

The Global Pulsed Field Ablation Market will grow from USD 1.13 Billion in 2025 to USD 1.97 Billion by 2031 at a 9.71% CAGR. Pulsed Field Ablation is a nonthermal cardiac ablation modality that utilizes irreversible electroporation to isolate pulmonary veins by creating pores in cell membranes to treat atrial fibrillation. The market is primarily driven by the technology's ability to minimize damage to collateral structures like the esophagus and phrenic nerve while significantly reducing procedure times compared to thermal energy sources. Additionally, the increasing global burden of arrhythmias necessitates more efficient workflow solutions in electrophysiology laboratories to manage rising patient volumes.

However, the high initial capital expenditure for console installation and catheter consumables remains a significant barrier to widespread adoption in cost sensitive healthcare environments. Despite this financial hurdle, clinical uptake is expanding rapidly in established markets where regulatory approval has been granted. According to the European Heart Rhythm Association, in 2025, Pulsed Field Ablation was utilized in 49% of first atrial fibrillation ablation procedures across surveyed European centers. This indicates a strong shift in medical preference toward this energy modality.

Key Market Drivers

The Rising Prevalence of Atrial Fibrillation and Cardiac Arrhythmias serves as a primary catalyst for market expansion, necessitating advanced interventions like Pulsed Field Ablation. As patient numbers swell due to aging demographics and lifestyle factors, the demand for effective treatments has outpaced historical projections, forcing healthcare systems to seek modalities that can handle higher procedural volumes. According to MountainView Regional Medical Center, February 2025, updated estimates indicate that the national prevalence of atrial fibrillation in the United States has reached at least 10.5 million adults, a figure significantly higher than previous long-term projections. This surging burden compels healthcare providers to adopt PFA systems that offer speed and safety, ensuring high throughput in electrophysiology labs to manage the escalating caseload.

Concurrently, the Acceleration in Regulatory Approvals and Strategic Product Launches has dramatically reshaped the competitive landscape and fueled rapid commercial adoption. Major medtech corporations are aggressively commercializing their PFA platforms, resulting in immediate and substantial revenue impacts as physicians transition away from thermal energy sources. According to Medical Device Network, October 2025, Boston Scientific reported a 22.4% increase in its cardiovascular business revenue, reaching over $3.3 billion in the third quarter, largely attributed to the robust uptake of its Farapulse system. This commercial momentum is further evidenced by significant capital inflows into emerging competitors aiming to bring next-generation solutions to market. For instance, according to MedTech Dive, July 2025, Kardium raised $250 million in financing to support the regulatory approval and commercial launch of its Globe pulsed field ablation system, highlighting the intense investment activity driving the sector forward.

Download Free Sample Report

Key Market Challenges

The high initial capital expenditure required for console installation and catheter consumables constitutes a substantial barrier to the expansion of the Global Pulsed Field Ablation Market. While the technology offers clinical efficiency, the financial burden of acquiring proprietary generators and expensive single-use devices limits adoption primarily to well-funded academic centers and private institutions. Community hospitals and healthcare systems in cost-sensitive regions often operate on fixed budgets that cannot accommodate the premium pricing of this novel modality compared to fully amortized thermal ablation systems. This economic pressure forces hospital administrators to scrutinize the return on investment heavily, often delaying procurement until reimbursement structures align more closely with the elevated operational costs.

The disparity in procedural expenses significantly hampers the technology's ability to displace standard of care treatments in the broader market. According to the Heart Rhythm Society, in 2024, a real-world comparative analysis indicated that Pulsed Field Ablation procedures incurred a considerably higher median total cost of approximately £10,010 compared to £8,106 for cryoballoon ablation, a difference largely driven by the premium costs of equipment and disposables. This cost differential creates a difficult value proposition for purchasing departments, restricting the technology’s market penetration to facilities that can absorb the incremental expense or those with specific high-tier reimbursement contracts.

Key Market Trends

The Integration with Advanced 3D Electroanatomical Mapping Systems is fundamentally altering the procedural landscape by addressing the visualization limitations of early single-shot devices. Manufacturers are increasingly prioritizing the development of catheters that seamlessly interface with proprietary mapping platforms, allowing electrophysiologists to visualize real-time catheter location and tissue contact metrics during energy delivery. This technological synergy enhances lesion precision and safety, facilitating the treatment of complex arrhythmias where blind catheter positioning is insufficient. According to TCTMD, December 2025, the FDA approval of the Volt pulsed-field ablation system was supported by clinical data demonstrating a 93.1% freedom from arrhythmia recurrence in patients with paroxysmal atrial fibrillation, a high efficacy rate largely attributed to the system's capability to provide real-time contact visualization during procedures.

The Expansion of Clinical Indications to Ventricular Tachycardia represents a critical frontier for market growth, leveraging the tissue-selective nature of electroporation to treat high-risk ventricular arrhythmias. Unlike thermal modalities, which pose risks to sensitive cardiac structures during deep ventricular burns, pulsed field energy offers a safer profile for penetrating thick ventricular scar tissue without collateral damage. This capability is driving robust investigational activity aimed at establishing PFA as a viable standard for life-threatening ventricular rhythm disorders, significantly broadening the addressable patient population beyond atrial fibrillation. According to the Heart Rhythm Society, April 2025, results from the First-in-Human VCAS Trial revealed that a specialized contact force PFA system achieved a 78% rate of freedom from scar-related ventricular tachycardia, highlighting the modality's potential to redefine treatment outcomes in this challenging therapeutic area.

Segmental Insights

The Catheters segment is positioned as the fastest-growing category within the Global Pulsed Field Ablation Market, primarily due to the recurring consumption of these single-use devices during cardiac procedures. As the essential interface for delivering energy to targeted tissues, their demand scales directly with the rising volume of atrial fibrillation treatments. This trajectory is reinforced by recent approvals from the U.S. Food and Drug Administration, which have expanded commercial availability and validated the safety profile of these tools. Consequently, clinical adoption is accelerating as providers seek efficient, non-thermal solutions for arrhythmia management.

Regional Insights

North America currently maintains a leading position in the global pulsed field ablation market, primarily driven by the high prevalence of atrial fibrillation and other cardiac arrhythmias across the region. This dominance is supported by a robust healthcare infrastructure and the strong presence of major medical technology corporations that facilitate rapid product distribution. Furthermore, recent device approvals by the U.S. Food and Drug Administration have significantly accelerated clinical adoption and commercial availability. The region’s focus on minimally invasive cardiac interventions and favorable reimbursement structures further strengthens its established market authority.

Recent Developments

• In September 2025, Kardium Inc. announced that it received Premarket Approval from the U.S. FDA for its Globe Pulsed Field System. The regulatory decision also covered the Globe Introducer sheath and the system's mapping software. The platform combined high-density mapping and pulsed field ablation into a single catheter featuring a 122-electrode spherical array. It was designed to perform single-shot pulmonary vein isolation for patients with atrial fibrillation. This approval allowed the company to enter the United States market with a comprehensive solution that provided real-time feedback and durable lesion creation during ablation procedures.
• In March 2025, Abbott Laboratories secured CE Mark approval in Europe for its Volt Pulsed Field Ablation System, designed for treating atrial fibrillation. This regulatory clearance followed a clinical trial that assessed the system's safety and effectiveness. The Volt system was integrated with the company's EnSite X EP heart mapping technology to enhance visualization and positioning during procedures. The device featured a balloon-in-basket catheter designed to improve the precision of tissue targeting. The company announced that this approval allowed for the commercial launch of the system in European markets, providing a new therapeutic option for managing heart rhythm disorders.
• In October 2024, Medtronic received approval from the U.S. FDA for the Affera Mapping and Ablation System, which featured the Sphere-9 Catheter. This system integrated high-density mapping with the capability to deliver both pulsed field and radiofrequency ablation energies. It was indicated for the treatment of persistent atrial fibrillation and cavotricuspid isthmus-dependent atrial flutter. The company noted that this approval made it the first entity to offer two FDA-approved PFA technologies. The catheter's wide-area focal design allowed for treatment flexibility, enabling operators to switch between energy types during procedures to address specific patient anatomies.
• In January 2024, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) approved its FARAPULSE Pulsed Field Ablation (PFA) System. The device was indicated for isolating pulmonary veins to treat drug-refractory, recurrent, symptomatic, paroxysmal atrial fibrillation. This approval marked the introduction of a PFA system designed specifically for this therapy into the U.S. market. The technology utilized tissue-selective, non-thermal electric fields to ablate heart tissue, offering an alternative to standard thermal ablation methods. The company stated that the system demonstrated safety and efficacy in clinical trials compared to conventional thermal ablation technologies.

Key Market Players

• Boston Scientific Corporation
• Abbott Laboratories Inc.
• Medtronic, Inc.
• Biosense Webster, Inc.
• Adagio Medical Inc.
• Kardium Inc.
• Pulse Biosciences, Inc.
• CardioFocus, Inc.
• Acutus Medical, Inc.
• Field Medical, Inc.

By Components	By Indication	By End Use	By Region
Catheters and Generators	Atrial Fibrillation and Non-Atrial Fibrillation	Inpatient and Outpatient	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pulsed Field Ablation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pulsed Field Ablation Market , By Components:

• Catheters and Generators

• Pulsed Field Ablation Market , By Indication:

• Atrial Fibrillation and Non-Atrial Fibrillation

• Pulsed Field Ablation Market , By End Use:

• Inpatient and Outpatient

• Pulsed Field Ablation Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE